---
figid: PMC7333221__fphar-11-00971-g001
figlink: pmc/articles/PMC7333221/figure/f1/
number: F1
caption: Origin of B-cell-associated malignant tumors and the anti-tumor mechanisms
  of HDAC6 inhibitors. (A) B lymphocytes originate from HSCs in bone marrow. CLPs
  undergo Pro-B cells, Pre-B cells, immature B cells stages and then transfer to the
  secondary lymphoid tissues (lymph nodes) via blood vessel. Naive B cells continue
  to develop into plasma cells or memory B cells after antigen stimulation. Abnormalities
  in different stages of B cell development can lead to different malignant events.
  MCL, mantle cell lymphoma; BL, Burkitt lymphoma; GCB DLBCL, germinal center B cell-like
  diffuse large B cell lymphoma; ABC DLBCL, activated B cell–like diffuse large B
  cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma. (B) HDAC6 can promote
  c-Myc expression by upregulating FOXO1 or β-catenin. At the same time c-Myc can
  promote HDAC6 expression, thereby promoting the survival of tumor cells. The simultaneous
  target of c-Myc and HDAC6 can effectively induce apoptosis of tumor cells. (C) HDAC6
  is involved in the aggresomal pathway of protein degradation. HDAC6 inhibitors cause
  ER stress by inhibiting this pathway. In addition, HDAC6 can induce UPR by directly
  targeting GRP78, and ultimately induce apoptosis. (D) MM cells achieve immune escape
  through the PD-1/PD-L1 axis. HDAC6 inhibitors can inhibit the expression of PD-L1
  and PD-1, thereby promoting tumor cell death. (E) Tumor cells can survive by upregulating
  cell survival signaling pathways such as NF-κB, MAPK, and PI3K/AKT pathways. HDAC6
  inhibitors can promote apoptosis by inhibiting these signaling pathways.
pmcid: PMC7333221
papertitle: Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological
  Malignancies.
reftext: Jia Yang, et al. Front Pharmacol. 2020;11:971.
pmc_ranked_result_index: '104492'
pathway_score: 0.6373242
filename: fphar-11-00971-g001.jpg
figtitle: Origin of B-cell-associated malignant tumors and the anti-tumor mechanisms
  of HDAC6 inhibitors
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7333221__fphar-11-00971-g001.html
  '@type': Dataset
  description: Origin of B-cell-associated malignant tumors and the anti-tumor mechanisms
    of HDAC6 inhibitors. (A) B lymphocytes originate from HSCs in bone marrow. CLPs
    undergo Pro-B cells, Pre-B cells, immature B cells stages and then transfer to
    the secondary lymphoid tissues (lymph nodes) via blood vessel. Naive B cells continue
    to develop into plasma cells or memory B cells after antigen stimulation. Abnormalities
    in different stages of B cell development can lead to different malignant events.
    MCL, mantle cell lymphoma; BL, Burkitt lymphoma; GCB DLBCL, germinal center B
    cell-like diffuse large B cell lymphoma; ABC DLBCL, activated B cell–like diffuse
    large B cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma. (B) HDAC6
    can promote c-Myc expression by upregulating FOXO1 or β-catenin. At the same time
    c-Myc can promote HDAC6 expression, thereby promoting the survival of tumor cells.
    The simultaneous target of c-Myc and HDAC6 can effectively induce apoptosis of
    tumor cells. (C) HDAC6 is involved in the aggresomal pathway of protein degradation.
    HDAC6 inhibitors cause ER stress by inhibiting this pathway. In addition, HDAC6
    can induce UPR by directly targeting GRP78, and ultimately induce apoptosis. (D)
    MM cells achieve immune escape through the PD-1/PD-L1 axis. HDAC6 inhibitors can
    inhibit the expression of PD-L1 and PD-1, thereby promoting tumor cell death.
    (E) Tumor cells can survive by upregulating cell survival signaling pathways such
    as NF-κB, MAPK, and PI3K/AKT pathways. HDAC6 inhibitors can promote apoptosis
    by inhibiting these signaling pathways.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HDAC6
  - MYC
  - CLEC4D
  - CD48
  - PDC
  - NFKB1
  - NFKB2
  - REL
  - RELA
  - RELB
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - AKT2
  - AKT3
  - AKT1
  - MAPK3
  - MAPK1
  - MAPK14
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK9
  - MAPK10
  - FOXO1
  - CTNNB1
  - HSPA5
  - EIF2AK3
  - CD274
  - PDCD1
genes:
- word: HDAC6
  symbol: HDAC6
  source: hgnc_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: c-Myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: MCL
  symbol: MCL
  source: hgnc_alias_symbol
  hgnc_symbol: CLEC4D
  entrez: '338339'
- word: HDAC6
  symbol: HDAC6
  source: hgnc_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: blast
  symbol: BLAST
  source: hgnc_alias_symbol
  hgnc_symbol: CD48
  entrez: '962'
- word: HDAC6
  symbol: HDAC6
  source: hgnc_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: pDC
  symbol: PDC
  source: hgnc_symbol
  hgnc_symbol: PDC
  entrez: '5132'
- word: blast
  symbol: BLAST
  source: hgnc_alias_symbol
  hgnc_symbol: CD48
  entrez: '962'
- word: HDAC6
  symbol: HDAC6
  source: hgnc_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K/AKTsignalingt
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: HDAC6
  symbol: HDAC6
  source: hgnc_symbol
  hgnc_symbol: HDAC6
  entrez: '10013'
- word: c-Myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: FOXO1
  symbol: FOXO1
  source: hgnc_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: B-catenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: GRP78
  symbol: GRP78
  source: hgnc_prev_symbol
  hgnc_symbol: HSPA5
  entrez: '3309'
- word: PERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
chemicals: []
diseases: []
figid_alias: PMC7333221__F1
redirect_from: /figures/PMC7333221__F1
figtype: Figure
---
